Golish will support Medacta’s U.S. subsidiary in its spine product development and commercial activities, helping the company expand upon its culture of collaboration, clinical excellence, and evidence-based and patient-centric innovation.
Golish is a fellowship-trained spinal surgeon, medical device and data scientist, and experienced healthcare administrator and executive. He currently acts as medical director of spinal surgery and of clinical trials at Jupiter Medical Center (Jupiter, Fla.) and is a practicing spinal surgeon at Florida Spine Center in Palm Beach, Fla. He serves as chairman of the American Academy of Orthopaedic Surgeons (AAOS) Biomedical Engineering Committee and chairman and director of the board for the Research Committee of the North American Spine Foundation. From 2012 to 2016, he was a voting member on the U.S. Food and Drug Administration’s Orthopaedic and Rehabilitation Devices Panel. Golish received his Ph.D. and medical degree from the University of California, Los Angeles in 2002 and 2004, respectively. He completed his spinal surgery fellowship at Stanford University in 2010 and received his M.B.A. from Duke University in 2013.
“With his diverse experience as a surgeon, medical data scientist and expert in U.S. regulatory affairs, Dr. Golish will be an important addition to the Medacta spine team as it continues to introduce methodical, thoughtful, and evidence-based innovations,” said Francesco Siccardi, executive vice president of Medacta International. “His steadfast dedication to patient safety and the role that medical device innovation can play in improving life aligns well with our ideals at Medacta, and we are thrilled to have him on board as we look to meet our ambitious growth targets in the year ahead.”
Golish joins Medacta following an impactful year. The company’s Spine Division experienced more than 140 percent sales growth in 2016 and now boasts five consecutive quarters of 24 percent quarter-over-quarter growth. Last year, the Division increased its customer base by 105 percent and added more than 40 new field agents selling its products in the United States.
“Medacta’s key differentiator is its corporate culture, which focuses on excellence in patient care, quality, evidence and innovation in a way that moves the field forward while keeping safety paramount,” said Golish. “It’s an exciting time for Medacta as a whole, but especially for its Spine Division, which experienced transformative growth in 2016 and is poised to meet or even exceed upon the growth targets set for 2017.”
In 2016, Medacta’s Spine Division unveiled three new products, including the MySpine Low Profile Guide. Golish was one of the first U.S.-based surgeons to use the 3D-printed pedicle screw guide following its U.S. Food and Drug Administration clearance in October 2016. The pedicle screw guide builds on the MySpine Standard Profile, released in 2014.
Medacta International is a manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s approach and innovation have resulted in standard of care breakthroughs in hip replacement with the AMIS system and total knee replacement with MyKnee patient-matched technology. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in more than 30 countries.